

Frede Donskov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6439001/publications.pdf>

Version: 2024-02-01

230
papers

21,897
citations

30070

54
h-index

9345

143
g-index

235
all docs

235
docs citations

235
times ranked

18033
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	27.0	4,889
2	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334
3	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	27.0	1,004
4	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , The, 2013, 14, 141-148.	10.7	808
5	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	10.7	789
6	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	13.7	778
7	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254.	27.0	640
8	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
9	Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4709-4717.	1.6	385
10	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	1.9	382
11	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	4.5	343
12	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	1.6	316
13	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.	10.7	299
14	Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e98259.	2.5	279
15	Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. <i>New England Journal of Medicine</i> , 2021, 385, 2036-2046.	27.0	274
16	Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1997-2005.	1.6	271
17	Immunomonitoring and prognostic relevance of neutrophils in clinical trials. <i>Seminars in Cancer Biology</i> , 2013, 23, 200-207.	9.6	250
18	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. <i>Cancer</i> , 2012, 118, 2476-2485.	4.1	219

#	ARTICLE	IF	CITATIONS
19	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	1.9	209
20	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	1.9	207
21	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	4.1	201
22	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.	1.9	199
23	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	4.1	189
24	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68.	1.9	164
25	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.6	164
26	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
27	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	7.0	154
28	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	1.6	145
29	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	1.9	133
30	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , 2012, 23, 1549-1555.	1.2	121
31	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. <i>Annals of Oncology</i> , 2014, 25, 149-154.	1.2	121
32	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	10.7	112
33	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	5.9	104
34	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	4.1	103
35	Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome. <i>Lung Cancer</i> , 2013, 81, 130-137.	2.0	101
36	Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. <i>British Journal of Cancer</i> , 2013, 108, 2116-2122.	6.4	95

#	ARTICLE	IF	CITATIONS
37	Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2010, 102, 867-872.	6.4	89
38	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	6.4	88
39	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	1.6	83
40	Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 1052-1058.	7.0	80
41	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	1.9	78
42	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4500-4500.	1.6	78
43	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
44	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	4.1	74
45	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	1.9	71
46	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	1.9	71
47	Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. <i>European Journal of Cancer</i> , 2014, 50, 553-562.	2.8	69
48	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014, 65, 723-730.	1.9	69
49	Monocytes and neutrophils as "bad guys"™ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma " results from a randomised phase II trial. <i>British Journal of Cancer</i> , 2006, 94, 218-226.	6.4	67
50	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	1.9	65
51	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014, 110, 1917-1922.	6.4	64
52	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
53	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.	1.6	61
54	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016, 65, 102-108.	2.8	60

#	ARTICLE	IF	CITATIONS
55	Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2013, 71, 1532-1540.	1.2	57
56	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 609-609.	1.6	51
57	Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. <i>British Journal of Cancer</i> , 2002, 87, 194-201.	6.4	50
58	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013.	7.0	48
59	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	3.6	47
60	Sunitinib-induced hypertension, neutropaenia and thrombocytopenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2016, 117, 110-117.	2.5	47
61	Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 729-739.	4.2	45
62	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	1.9	44
63	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	1.6	43
64	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2019, 37, 546-546.	1.6	42
65	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	1.9	41
66	Phase II study of the oral HIF-2 α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5003-5003.	1.6	40
67	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	1.9	39
68	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 902-909.	2.8	37
69	Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. <i>Annals of Oncology</i> , 2018, 29, 2098-2104.	1.2	36
70	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	1.9	33
71	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	5.4	31
72	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4512-4512.	1.6	30

#	ARTICLE	IF	CITATIONS
73	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	5.4	29
74	661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). <i>Annals of Oncology</i> , 2021, 32, S685-S687.	1.2	29
75	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020, 59, 652-659.	1.8	28
76	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4507-4507.	1.6	28
77	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	1.9	26
78	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	5.4	26
79	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	4.4	25
80	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	1.9	25
81	Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2005, 93, 757-762.	6.4	24
82	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 617-617.	1.6	24
83	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Current Oncology</i> , 2019, 26, 175-179.	2.2	23
84	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173.	7.0	23
85	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4569-4569.	1.6	23
86	von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. <i>European Journal of Medical Genetics</i> , 2022, 65, 104538.	1.3	23
87	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 115-125.	2.8	22
88	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	2.8	22
89	Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients With Metastatic Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2014, 49, 601-607.	6.2	21
90	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. <i>Annals of Oncology</i> , 2020, 31, S559-S560.	1.2	21

#	ARTICLE	IF	CITATIONS
91	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 773.	7.1	21
92	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 498-498.	1.6	21
93	Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon- γ in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. <i>Annals of Oncology</i> , 2002, 13, 441-449.	1.2	20
94	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	7.0	20
95	A randomized phase II trial of interleukin-2 and interferon- γ plus bevacizumab versus interleukin-2 and interferon- γ in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. <i>Acta Oncologica</i> , 2018, 57, 589-594.	1.8	19
96	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.	2.8	19
97	Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e32-e37.	1.9	18
98	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. <i>Cardio-Oncology</i> , 2021, 7, 27.	1.7	17
99	Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. <i>BJU International</i> , 2008, 101, 41-44.	2.5	15
100	A five-factor biomarker profile obtained week 4 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. <i>Acta Oncologica</i> , 2016, 55, 341-348.	1.8	15
101	Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma. <i>Investigative Radiology</i> , 2017, 52, 103-110.	6.2	15
102	Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 62-68.e2.	1.9	15
103	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	1.6	15
104	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 608-608.	1.6	15
105	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 403-410.e2.	1.9	14
106	Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. <i>Journal of Geriatric Oncology</i> , 2021, 12, 827-833.	1.0	14
107	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4570-4570.	1.6	14
108	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. <i>European Journal of Cancer</i> , 2022, 171, 124-132.	2.8	14
110	1141 POSTER Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC). <i>European Journal of Cancer</i> , 2011, 47, S136.	2.8	13
111	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2017, 81, 9-16.	2.8	13
112	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.4	13
113	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , 2020, 13, 59.	3.0	13
114	In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2004, 90, 626-631.	6.4	12
115	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017, 71, 970-978.	1.9	12
116	Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. <i>Annals of Oncology</i> , 2018, 29, viii309.	1.2	12
117	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	3.7	12
118	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	1.6	12
119	Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7911-7916.	7.0	11
120	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4509-4509.	1.6	11
121	Wildtype p53-specific Antibody and T-Cell Responses in Cancer Patients. <i>Journal of Immunotherapy</i> , 2011, 34, 629-640.	2.4	10
122	Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2. <i>European Urology</i> , 2015, 68, 516-522.	1.9	10
123	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	1.9	10
124	Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients. <i>British Journal of Radiology</i> , 2018, 91, 20160795.	2.2	10
125	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. <i>Kidney Cancer</i> , 2018, 2, 31-36.	0.4	10
126	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€” an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	1.0	10

#	ARTICLE	IF	CITATIONS
127	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 499-499.	1.6	10
128	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 564-564.	1.6	10
129	Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. Anticancer Research, 2003, 23, 537-42.	1.1	10
130	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	5.9	10
131	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2014, 12, 335-340.	1.9	9
132	The database of the Danish Renal Cancer Group. Clinical Epidemiology, 2016, Volume 8, 725-729.	3.0	9
133	Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. Acta Oncol ³ gica, 2018, 57, 522-527.	1.8	9
134	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	1.9	9
135	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2014, 32, 396-396.	1.6	9
136	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. Journal of Clinical Oncology, 2020, 38, 5024-5024.	1.6	9
137	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.	1.6	9
138	Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta Oncol ³ gica, 2018, 57, 1580-1585.	1.8	8
139	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A. Annals of Oncology, 2019, 30, v381-v382.	1.2	8
140	Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Danish Medical Bulletin, 2007, 54, 249-65.	0.3	8
141	Blood natural killer cells during treatment in recurrent ovarian cancer. Acta Oncol ³ gica, 2020, 59, 1365-1373.	1.8	7
142	<p>Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa) Tj ETQq0 0 0 rgB3.0 Overlock 10 Tf 50		
143	Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC). Annals of Oncology, 2012, 23, ix259.	1.2	7
144	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 398-398.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Pazopanib exposure-response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4564-4564.	1.6	7
146	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100829.	3.7	6
147	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5034-5034.	1.6	6
148	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5069-5069.	1.6	6
149	Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. <i>Acta Oncol</i> , 2022, 61, 58-63.	1.8	6
150	Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. <i>Natural Immunity</i> , 1996, 15, 134-46.	0.1	6
151	Outcome and prognosis after adrenal metastasectomy: nationwide study. <i>BJS Open</i> , 2022, 6, .	1.7	6
152	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Roentgenology</i> , 2022, 218, 867-876.	2.2	6
153	Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. <i>Immunopharmacology and Immunotoxicology</i> , 2013, 35, 487-496.	2.4	5
154	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	1.9	5
155	A randomized phase II trial of interleukin-2/interferon- γ plus bevacizumab versus interleukin-2/interferon- γ in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4563-4563.	1.6	5
156	Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 498-498.	1.6	5
157	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5063-5063.	1.6	5
158	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 684-684.	1.6	5
159	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. <i>European Radiology</i> , 2022, 32, 7323-7334.	4.5	5
160	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). <i>Annals of Oncology</i> , 2019, 30, v396.	1.2	4
161	Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 254-259.	1.9	4
162	Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma. <i>Acta Oncol</i> , 2020, 59, 13-19.	1.8	4

#	ARTICLE	IF	CITATIONS
163	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020, 6, 293-306.	1.8	4
164	Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4565-4565.	1.6	4
165	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 584-584.	1.6	4
166	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4536-4536.	1.6	4
167	GGrade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. <i>International Journal of Urology</i> , 2022, 29, 641-645.	1.0	4
168	Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments. <i>The Journal of Oncopathology</i> , 2014, 2, 1-9.	0.1	3
169	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 97-99.	2.4	3
170	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , 2018, 29, viii315.	1.2	3
171	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. <i>Annals of Oncology</i> , 2018, 29, viii308.	1.2	3
172	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.	1.9	3
173	Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need. <i>Annals of Translational Medicine</i> , 2021, 9, 97-97.	1.7	3
174	Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). <i>Cancer Research</i> , 2021, 81, CT188-CT188.	0.9	3
175	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015, 33, 430-430.	1.6	3
176	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 639-639.	1.6	3
177	genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). <i>Annals of Oncology</i> , 2016, 27, vi565.	1.2	2
178	Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician. <i>Oncology and Therapy</i> , 2018, 6, 1-7.	2.6	2
179	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.4	2
180	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. <i>European Radiology Experimental</i> , 2021, 5, 32.	3.4	2

#	ARTICLE	IF	CITATIONS
181	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, 394-394.	1.6	2
182	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 517-517.	1.6	2
183	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 615-615.	1.6	2
184	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.. Journal of Clinical Oncology, 2020, 38, 5068-5068.	1.6	2
185	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5071-5071.	1.6	2
186	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 317-317.	1.6	2
187	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 308-308.	1.6	2
188	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. BJU International, 2021, 128, 254-261.	2.5	1
189	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2021, 39, 4554-4554.	1.6	1
190	Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clinical Epidemiology, 2021, Volume 13, 871-882.	3.0	1
191	First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, 4586-4586.	1.6	1
192	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 4506-4506.	1.6	1
193	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2016, 34, 4570-4570.	1.6	1
194	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 544-544.	1.6	1
195	Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.. Journal of Clinical Oncology, 2018, 36, 576-576.	1.6	1
196	Tissue immune response in epithelial ovarian carcinoma.. Journal of Clinical Oncology, 2019, 37, 2625-2625.	1.6	1
197	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. Journal of Clinical Oncology, 2019, 37, 610-610.	1.6	1
198	Metastatic non-“clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. Journal of Clinical Oncology, 2013, 31, 396-396.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, e15578-e15578.	1.6	1
200	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. Journal of Clinical Oncology, 2016, 34, 552-552.	1.6	1
201	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 503-503.	1.6	1
202	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4570-4570.	1.6	1
203	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4578-4578.	1.6	1
204	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 4577-4577.	1.6	1
205	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 310-310.	1.6	1
206	Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.. Journal of Clinical Oncology, 2022, 40, 4538-4538.	1.6	1
207	Hypertension, Neutropenia, Thrombocytopenia, Normal Sodium and Ldh Within the First 12 Weeks of Treatment As Independent Biomarkers of Outcome in Metastatic Renal Cell Carcinoma (Mrcc). Annals of Oncology, 2014, 25, iv284.	1.2	0
208	The Advent of Psycho-oncology in Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 650-651.	3.1	0
209	Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Annals of Oncology, 2017, 28, v311-v312.	1.2	0
210	59â€¦Natural killer cells and treatment effect in recurrent ovarian cancer. , 2019, , .		0
211	18F-FDG Uptake in a Mesonephric Carcinoma. Clinical Nuclear Medicine, 2020, 45, 696-699.	1.3	0
212	425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology, 2020, 31, S1408.	1.2	0
213	First-line therapy in patients with metastatic renal cell carcinoma (mRCC): Results from consecutive patients over 25 years in a single institution.. Journal of Clinical Oncology, 2021, 39, e16574-e16574.	1.6	0
214	666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A. Annals of Oncology, 2021, 32, S691-S692.	1.2	0
215	662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced nonâ€“clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B. Annals of Oncology, 2021, 32, S687.	1.2	0
216	Blood Volume as a new functional image-based biomarker of progression inâ€“metastatic renal cell carcinoma. Scientific Reports, 2021, 11, 19659.	3.3	0

#	ARTICLE	IF	CITATIONS
217	Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage.. Journal of Clinical Oncology, 2012, 30, e21110-e21110.	1.6	0
218	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 4538-4538.	1.6	0
219	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, e15518-e15518.	1.6	0
220	Tumor-associated CD66b+ neutrophil and CD8+ lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments.. Journal of Clinical Oncology, 2013, 31, 5532-5532.	1.6	0
221	Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.. Journal of Clinical Oncology, 2013, 31, 4578-4578.	1.6	0
222	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, 4558-4558.	1.6	0
223	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. Journal of Clinical Oncology, 2016, 34, 534-534.	1.6	0
224	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. Journal of Clinical Oncology, 2016, 34, 4554-4554.	1.6	0
225	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 4510-4510.	1.6	0
226	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2017, 35, e16065-e16065.	1.6	0
227	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	1.6	0
228	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. Journal of Clinical Oncology, 2019, 37, 4578-4578.	1.6	0
229	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2020, 38, 5070-5070.	1.6	0
230	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. Journal of Clinical Oncology, 2020, 38, 701-701.	1.6	0